Pharmacological management, and potentially inappropriate prescriptions in patients with osteoporosis

References

• Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1–46.
   PubMed Web of Science ®Google Scholar
• Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–376.
   PubMed Web of Science ®Google Scholar
• Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46–56.
   PubMed Web of Science ®Google Scholar
• Briot K, Roux C, Thomas T, et al. 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine. 2018;85(5):519–530.
   PubMed Web of Science ®Google Scholar
• Medina Orjuela A, Rosero Olarte Ó, Nel Rueda Plata P, et al. II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica. Rev Colomb Reumatol. 2018;25(3):184–210.
   Google Scholar
• Munson JC, Bynum JP, Bell JE, et al. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med. 2016;176(10):1531–1538.
   PubMed Web of Science ®Google Scholar
• Cehic M, Lerner RG, Achten J, et al. Prescribing and adherence to bone protection medications following hip fracture in the United Kingdom: results from the World Hip trauma evaluation (WHiTE) cohort study. Bone Joint J. 2019;101(11):1402–1407.
   PubMedGoogle Scholar
• Devold HM, Doung GM, Tverdal A, et al. Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. Eur J Clin Pharmacol. 2010;66(3):299–306.
   PubMed Web of Science ®Google Scholar
• Siris ES, Modi A, Tang J, et al. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Curr Med Res Opin. 2014;30(1):123–130.
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Caffarelli C, Rossi S, et al. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study. Aging Clin Exp Res. 2016;28(3):459–468.
   PubMed Web of Science ®Google Scholar
• Franco J-S, Vizcaya D. Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: a systematic review. Pharmacol Res Perspect. 2020;8(5):e00661.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013;57(2):423–428.
   PubMed Web of Science ®Google Scholar
• Hollingworth SA, Gunanti I, Nissen LM, et al. Secondary prevention of osteoporosis in Australia: analysis of government-dispensed prescription data. Drugs Aging. 2010;27(3):255–264.
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. National osteoporosis foundation. clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.
   PubMed Web of Science ®Google Scholar
• Sanfélix-Genovés J, Sanfélix-Gimeno G, Peiró S, et al. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporos Int. 2013;24(3):1045–1055.
   PubMed Web of Science ®Google Scholar
• Valladales-Restrepo LF, Durán-Lengua M, Castro-Osorio EE, et al. Características sociodemográficas, clínicas y farmacológicas de adultos mayores con fracturas, en tres centros de referencia, Colombia. CES Medicina. 2020;34(1):14–26.
   Google Scholar
• Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929–1937.
   PubMed Web of Science ®Google Scholar
• Klop C, Gibson-Smith D, Elders PJ, et al. Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010. Osteoporos Int. 2015;26(7):1919–1928.
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Caffarelli C, Iolascon G, et al. Prescription of anti-osteoporosis medications after hospitalization for Hip fracture: a multicentre Italian survey. Aging Clin Exp Res. 2017;29(5):1031–1037.
   PubMed Web of Science ®Google Scholar
• Sjöberg C, Bladh L, Klintberg L, et al. Treatment with fall-risk-increasing and fracture-preventing drugs before and after a hip fracture: an observational study. Drugs Aging. 2010;27(8):653–661.
   PubMed Web of Science ®Google Scholar
• Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124(6):519–526.
   PubMed Web of Science ®Google Scholar
• Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.
   PubMed Web of Science ®Google Scholar
• Wu Q, Bencaz AF, Hentz JG, et al. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int. 2012;23(1):365–375.
   PubMed Web of Science ®Google Scholar
• Wu Q, Qu W, Crowell MD, et al. Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies. J Bone Miner Res. 2013;28(4):753–763.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537.
   PubMed Web of Science ®Google Scholar
• Machado-Alba J, Alzate-Carvajal V, Mondragón-Cardona A, et al. Baja frecuencia de prescripción de profilaxis para osteoporosis en pacientes en tratamiento crónico con corticoides en Colombia [Low frequency of prophylaxis prescription for osteoporosis in patients receiving chronic treatment with corticosteroids in Colombia]. Rev Peru Med Exp Salud Publica. 2013;30(1):26–30.
   PubMedGoogle Scholar
• Sternberg SA, Guy-Alfandary S, Rochon PA. Prescribing cascades in older adults. Can Med Assoc J. 2021;193(6):E215.
   Web of Science ®Google Scholar
• Kapugi M, Cunningham K. Corticosteroids. Orthop Nurs. 2019;38(5):336–339.
   PubMed Web of Science ®Google Scholar
• Sostres C, Lanas A. Gastroprotección en el paciente de edad avanzada: cuándo y cómo [Gastroprotection in the patient of advanced age: when and how]. Rev Esp Geriatr Gerontol. 2012;47(3):93–95.
   PubMedGoogle Scholar
• Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. Am Fam Physician. 2019;100(1):32–38.
   PubMed Web of Science ®Google Scholar